PL1677777T3 - Granulki zawierające chlorowodorek venlafaxiny - Google Patents

Granulki zawierające chlorowodorek venlafaxiny

Info

Publication number: PL1677777T3
Authority: PL; Poland
Prior art keywords: weight; pellets; venlafaxine hydrochloride; pellets containing; chloride
Prior art date: 2003-10-10

Application number

PL04791654T

Other languages

English (en)

Inventor

Pál Fekete

Tibor Korbély

Agnes Bozso

Eszter Moricz

Original Assignee

Egis Gyogyszergyar Nyrt

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-10

Filing date

2004-10-08

Publication date

2007-08-31

2004-10-08 Application filed by Egis Gyogyszergyar Nyrt filed Critical Egis Gyogyszergyar Nyrt

2007-08-31 Publication of PL1677777T3 publication Critical patent/PL1677777T3/pl

Links

239000008188 pellet Substances 0.000 title abstract 4
229960002416 venlafaxine hydrochloride Drugs 0.000 title abstract 3
QYRYFNHXARDNFZ-UHFFFAOYSA-N venlafaxine hydrochloride Chemical compound [H+].[Cl-].C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 QYRYFNHXARDNFZ-UHFFFAOYSA-N 0.000 title abstract 3
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 abstract 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 2
229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
239000004480 active ingredient Substances 0.000 abstract 1
239000000654 additive Substances 0.000 abstract 1
238000013270 controlled release Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
239000008108 microcrystalline cellulose Substances 0.000 abstract 1
229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
238000005453 pelletization Methods 0.000 abstract 1
239000000546 pharmaceutical excipient Substances 0.000 abstract 1
239000001103 potassium chloride Substances 0.000 abstract 1
235000011164 potassium chloride Nutrition 0.000 abstract 1
230000001737 promoting effect Effects 0.000 abstract 1
239000011780 sodium chloride Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
General Chemical & Material Sciences (AREA)
Psychiatry (AREA)
Organic Chemistry (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Emergency Medicine (AREA)
Inorganic Chemistry (AREA)
Pain & Pain Management (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

PL04791654T 2003-10-10 2004-10-08 Granulki zawierające chlorowodorek venlafaxiny PL1677777T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
HU0303382A HUP0303382A2 (hu)	2003-10-10	2003-10-10	Venlafaxin-hidroklorid-tartalmú pelletek
EP04791654A EP1677777B1 (en)	2003-10-10	2004-10-08	Pellets containing venlafaxine hydrochloride
PCT/HU2004/000095 WO2005034930A1 (en)	2003-10-10	2004-10-08	Pellets containing venlafaxine hydrochloride

Publications (1)

Publication Number	Publication Date
PL1677777T3 true PL1677777T3 (pl)	2007-08-31

Family

ID=90001704

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL379541A PL379541A1 (pl)	2003-10-10	2004-10-08	Granulki zawierające chlorowodorek venlafaxiny
PL04791654T PL1677777T3 (pl)	2003-10-10	2004-10-08	Granulki zawierające chlorowodorek venlafaxiny

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL379541A PL379541A1 (pl)	2003-10-10	2004-10-08	Granulki zawierające chlorowodorek venlafaxiny

Country Status (22)

Country	Link
EP (1)	EP1677777B1 (pl)
CN (1)	CN1882321B (pl)
AT (1)	ATE359771T1 (pl)
AU (1)	AU2004280132B2 (pl)
BG (1)	BG109539A (pl)
CY (1)	CY1106693T1 (pl)
CZ (1)	CZ2006269A3 (pl)
DE (1)	DE602004006009T2 (pl)
DK (1)	DK1677777T3 (pl)
EA (1)	EA009695B1 (pl)
ES (1)	ES2285538T3 (pl)
HR (2)	HRP20070322T3 (pl)
HU (1)	HUP0303382A2 (pl)
IL (1)	IL174830A (pl)
NO (1)	NO20062082L (pl)
PL (2)	PL379541A1 (pl)
PT (1)	PT1677777E (pl)
RS (2)	RS20060252A (pl)
SI (1)	SI1677777T1 (pl)
SK (1)	SK50442006A3 (pl)
UA (1)	UA82268C2 (pl)
WO (1)	WO2005034930A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU764453B2 (en)	1999-10-29	2003-08-21	Euro-Celtique S.A.	Controlled release hydrocodone formulations
US10179130B2 (en)	1999-10-29	2019-01-15	Purdue Pharma L.P.	Controlled release hydrocodone formulations
MXPA03003895A (es)	2000-10-30	2003-07-28	Euro Celtique Sa	Formulaciones de hidrocodona de liberacion controlada.
IL146462A (en)	2001-11-13	2015-02-26	Lycored Bio Ltd	Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
WO2007016315A2 (en) *	2005-07-28	2007-02-08	Dr. Reddy's Laboratories Ltd.	Extended release venlafaxine compositions
EA014262B1 (ru) *	2006-05-19	2010-10-29	Эгиш Дьёдьсердьяр Ньильваношан Мюкёдё Ресвеньтаршашаг	Способ получения гранулированной массы
US8445018B2 (en)	2006-09-15	2013-05-21	Cima Labs Inc.	Abuse resistant drug formulation
CA2798702A1 (en)	2010-05-11	2011-11-17	Cima Labs Inc.	Alcoholresistant metoprolol-containing extended-release oral dosage forms
WO2011143119A1 (en) *	2010-05-11	2011-11-17	Cima Labs Inc.	Alcohol-resistant extended release dosage forms comprising venlafaxine
EP2934487A1 (en) *	2012-12-19	2015-10-28	ratiopharm GmbH	Film coated pellets
CN103893151B (zh) *	2012-12-31	2018-04-27	石药集团中奇制药技术（石家庄）有限公司	一种盐酸文拉法辛缓释胶囊及其制备方法
WO2015065547A1 (en)	2013-10-31	2015-05-07	Cima Labs Inc.	Immediate release abuse-deterrent granulated dosage forms
US12589083B2 (en)	2019-05-07	2026-03-31	Clexio Biosciences Ltd.	Abuse-deterrent dosage forms containing esketamine
US11324707B2 (en)	2019-05-07	2022-05-10	Clexio Biosciences Ltd.	Abuse-deterrent dosage forms containing esketamine
CN114028577B (zh) *	2021-10-20	2024-07-02	珠海市东辰制药有限公司	一种二氧化硅丸芯及其制备方法
CN119868294B (zh) *	2024-11-08	2026-02-03	迪沙药业集团有限公司	一种利格列汀药物组合物及制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1331003B1 (en) *	1996-03-25	2015-08-26	Wyeth LLC	Extended release formulation containing venlafaxine
PE57198A1 (es) *	1996-03-25	1998-10-10	American Home Prod	Formula de liberacion prolongada
UA77145C2 (en) *	1997-11-05	2006-11-15	Wyeth Corp	Extended release dosage formulation
CN1334080A (zh) *	2001-07-25	2002-02-06	成都康弘制药有限公司	盐酸万拉法新缓释片及其制备方法
IL146462A (en) *	2001-11-13	2015-02-26	Lycored Bio Ltd	Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
AU2003219117A1 (en) *	2002-03-28	2003-10-13	Synthon B.V.	Extended release venlafaxine formulations

2003
- 2003-10-10 HU HU0303382A patent/HUP0303382A2/hu unknown
2004
- 2004-08-10 UA UAA200605099A patent/UA82268C2/uk unknown
- 2004-10-08 WO PCT/HU2004/000095 patent/WO2005034930A1/en not_active Ceased
- 2004-10-08 DK DK04791654T patent/DK1677777T3/da active
- 2004-10-08 PT PT04791654T patent/PT1677777E/pt unknown
- 2004-10-08 RS YUP-2006/0252A patent/RS20060252A/sr unknown
- 2004-10-08 SK SK5044-2006A patent/SK50442006A3/sk unknown
- 2004-10-08 SI SI200430364T patent/SI1677777T1/sl unknown
- 2004-10-08 PL PL379541A patent/PL379541A1/pl not_active IP Right Cessation
- 2004-10-08 HR HR20070322T patent/HRP20070322T3/xx unknown
- 2004-10-08 EA EA200600675A patent/EA009695B1/ru not_active IP Right Cessation
- 2004-10-08 CZ CZ20060269A patent/CZ2006269A3/cs unknown
- 2004-10-08 ES ES04791654T patent/ES2285538T3/es not_active Expired - Lifetime
- 2004-10-08 AT AT04791654T patent/ATE359771T1/de active
- 2004-10-08 RS RS20060252A patent/RS52150B/sr unknown
- 2004-10-08 HR HR20060136A patent/HRP20060136A2/xx not_active Application Discontinuation
- 2004-10-08 DE DE602004006009T patent/DE602004006009T2/de not_active Expired - Lifetime
- 2004-10-08 PL PL04791654T patent/PL1677777T3/pl unknown
- 2004-10-08 AU AU2004280132A patent/AU2004280132B2/en not_active Ceased
- 2004-10-08 CN CN2004800330326A patent/CN1882321B/zh not_active Expired - Fee Related
- 2004-10-08 EP EP04791654A patent/EP1677777B1/en not_active Expired - Lifetime
2006
- 2006-04-06 IL IL174830A patent/IL174830A/en not_active IP Right Cessation
- 2006-05-09 NO NO20062082A patent/NO20062082L/no unknown
- 2006-05-10 BG BG109539A patent/BG109539A/bg unknown
2007
- 2007-07-02 CY CY20071100874T patent/CY1106693T1/el unknown

Also Published As

Publication number	Publication date
IL174830A (en)	2010-04-15
BG109539A (bg)	2006-11-30
HUP0303382A2 (hu)	2005-08-29
RS20060252A (sr)	2008-08-07
DE602004006009D1 (de)	2007-05-31
HK1098364A1 (en)	2007-07-20
ATE359771T1 (de)	2007-05-15
CN1882321A (zh)	2006-12-20
DE602004006009T2 (de)	2008-01-10
EP1677777A1 (en)	2006-07-12
UA82268C2 (uk)	2008-03-25
CY1106693T1 (el)	2012-05-23
EA200600675A1 (ru)	2006-08-25
CZ2006269A3 (cs)	2006-07-12
RS52150B (sr)	2012-08-31
ES2285538T3 (es)	2007-11-16
SK50442006A3 (sk)	2006-08-03
HRP20070322T3 (hr)	2007-09-30
HRP20060136A2 (en)	2006-06-30
DK1677777T3 (da)	2007-09-03
HUP0303382D0 (en)	2003-12-29
PT1677777E (pt)	2007-06-21
SI1677777T1 (sl)	2007-10-31
AU2004280132A1 (en)	2005-04-21
IL174830A0 (en)	2008-04-13
EA009695B1 (ru)	2008-02-28
PL379541A1 (pl)	2006-10-02
WO2005034930A1 (en)	2005-04-21
NO20062082L (no)	2006-05-09
AU2004280132B2 (en)	2009-10-22
CN1882321B (zh)	2011-06-08
EP1677777B1 (en)	2007-04-18

Publication	Publication Date	Title
PL1677777T3 (pl)	2007-08-31	Granulki zawierające chlorowodorek venlafaxiny
MX2010013766A (es)	2011-03-15	Rasagilina para modificacion de enfermedad de parkinson.
SG153830A1 (en)	2009-07-29	Galenic formulations of organic compounds
MX2010007672A (es)	2010-10-07	Composicion estabilizada de liberacion sostenida de clorhidrato de bupropion y proceso para su preparacion.
SG158168A1 (en)	2010-01-29	5ht2c receptor modulator compositions and methods of use
WO2009028495A1 (ja)	2009-03-05	真菌性皮膚炎用剤
JO2973B1 (en)	2016-03-15	Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol
IS7398A (is)	2004-08-12	Lyfjablanda sem felur í sér N-((1-N-bútýl-4-píperídínýl)metýl)-3,4-díhýdró-2H-(1,3)oxasínó(3,2-A)indól-10-karboxamíð eða salt og aðferð þar að lútandi sem felur í sér þurrkornamyndun
WO2003072030A3 (en)	2004-01-22	Methods for preventing or treating cardiac arrhythmia
PL1711169T3 (pl)	2007-10-31	Powlekane tabletki chlorowodorku wenlafaksyny o wydłużonym czasie uwalniania
HRP20100120T1 (hr)	2010-04-30	Formulacije s valsartanom
HRP20100373T4 (hr)	2016-12-16	Upotreba kombinacije morfina s najmanje jednim opijatnim antagonistom u liječenju ovisnosti o opijatima i u sprječavanju neoralne zloupotrebe opijata kod ovisnika opijatima
JP2011516544A5 (pl)	2013-08-01
EA201170784A1 (ru)	2011-12-30	Гранулы тамсулозина для фиксированной комбинации
MX2010003594A (es)	2010-09-22	Formas cristalinas de sal sodica de dmxaa.
MX2007014963A (es)	2008-04-17	Composicion de liberacion modificada de al menos una forma de venlafaxina.
MXPA06000363A (es)	2006-03-28	Forma de dosificacion oral de mesilato de saquinavir.
PL1589014T3 (pl)	2008-01-31	Sposób syntezy pochodnych 1,3-dihydro-2H-3-benzazepin-2-onu i jego zastosowanie do wytwarzania iwabradyny i jej dopuszczalnych farmaceutycznie soli
SG170037A1 (en)	2011-04-29	Compositions useful for reducing nephrotoxicity and methods of use thereof
WO2007069033A3 (en)	2007-10-04	Pharmaceutical compositions comprising dexibuprofen, an opiate analgesic and paracetamol
WO2005115092A3 (en)	2006-03-23	Micronized oral pharmaceutical composition
WO2006064321A3 (en)	2007-12-27	Controlled release compositions of divalproex sodium
EA200600932A1 (ru)	2006-10-27	Таблетки циталопрама гидробромида
TNSN06242A1 (en)	2007-12-03	Extended release coated minitablets of venlafaxine hydrochloride
UA99678C2 (ru)	2012-09-10	КОМБИНИРОВАННАЯ ДОЗИРОВАННАЯ ФОРМА, СОДЕРЖАЩАЯ ТАМСУЛОЗИН И ИНГИБИТОР ТЕСТОСТЕРОН-5α-РЕДУКТАЗЫ